YCM
TBPH

Yakira Capital Management’s Theravance Biopharma TBPH Stock Holding History

Yakira Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,622
Closed -$184K – 226
2025
Q3 		$184K Hold
12,622
– – 0.06% 114
2025
Q2 		$139K Sell
12,622
-2,500
-17% -$24.3K 0.05% 121
2025
Q1 		$135K Hold
15,122
– – 0.05% 113
2024
Q4 		$142K Hold
15,122
– – 0.05% 116
2024
Q3 		$122K Hold
15,122
– – 0.04% 120
2024
Q2 		$128K Hold
15,122
– – 0.05% 117
2024
Q1 		$136K Hold
15,122
– – 0.04% 130
2023
Q4 		$170K Sell
15,122
-1,776
-11% -$17.9K 0.06% 134
2023
Q3 		$146K Hold
16,898
– – 0.04% 148
2023
Q2 		$175K Sell
16,898
-15,758
-48% -$174K 0.05% 147
2023
Q1 		$354K Buy
32,656
+1,128
+4% +$11.9K 0.09% 134
2022
Q4 		$354K Sell
31,528
-27,572
-47% -$290K 0.07% 157
2022
Q3 		$599K Buy
+59,100
New +$554K 0.09% 190

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Yakira Capital Management's TBPH Position: Q4 2025 in Review

Yakira Capital Management sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 12,622 shares — an estimated $184K sold.

Yakira Capital Management first reported a position in TBPH in Q3 2022 and held it in 13 quarters. The position peaked at $599K in Q3 2022. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Yakira Capital Management reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • Yakira Capital Management sold 12,622 Theravance Biopharma shares in Q4 2025, an estimated $184K.
  • Yakira Capital Management first reported a position in Theravance Biopharma in Q3 2022 and held it in 13 quarters.
  • Yakira Capital Management's Theravance Biopharma position peaked at $599K in Q3 2022.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Yakira Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.